Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-12 4:39 pm Purchase | 2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 200,621 10.250% | 86,000 (+75.03%) | Filing History |
| 2021-02-12 4:37 pm Purchase | 2020-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM | ORBIMED ADVISORS LLC | 484,525 4.970% | 90,116 (+22.85%) | Filing History |
| 2021-02-08 9:54 pm Unchanged | 2021-02-05 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 4,267,564 8.800% | 0 (Unchanged) | Filing History |
| 2021-01-28 8:30 pm Sale | 2021-01-22 | 13D | PREVAIL THERAPEUTICS INC PRVL | ORBIMED ADVISORS LLC | 0 0.000% | -13,822,463 (Position Closed) | Filing History |
| 2021-01-28 1:48 pm Unchanged | 2021-01-26 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 297,366 11.200% | 0 (Unchanged) | Filing History |
| 2021-01-21 4:46 pm Purchase | 2021-01-12 | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 29,853,364 9.100% | 29,853,364 (New Position) | Filing History |
| 2021-01-13 5:34 pm Purchase | 2021-01-11 | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 14,847,077 31.900% | 41,700 (+0.28%) | Filing History |
| 2020-12-30 4:27 pm Sale | 2020-12-28 | 13D | Alpine Immune Sciences, Inc. ALPN | ORBIMED ADVISORS LLC | 3,216,206 13.400% | -600,000 (-15.72%) | Filing History |